8-K: PAVmed Inc. Faces Nasdaq Delisting Notice and Completes Debt-for-Equity Swap

PAVmed Inc. received a delisting notice from Nasdaq due to its stock price falling below $1 and completed a debt-for-equity swap, issuing Series C Preferred Stock.

Summary

• PAVmed Inc. received a notification from Nasdaq on January 23, 2025, stating that its common stock had traded below the required $1 minimum for 30 consecutive business days.
• The company has been given 180 calendar days, until July 22, 2025, to regain compliance by maintaining a closing bid price of at least $1 for a minimum of ten consecutive business days.
• An additional 180-day period may be granted if the company does not regain compliance within the initial period.
• On January 24, 2025, PAVmed completed a sale of 2,653 shares of Series C Convertible Preferred Stock for approximately $2.653 million, satisfied by the cancellation of certain unsecured debt obligations.
• If all Series C Preferred Stock is converted at the voluntary conversion price of $1.068 per share, approximately 2,484,082 common shares would be issued.
• If converted at the floor price of $0.2136 per share, approximately 12,420,412 common shares would be issued.

Sentiment

Score: 3

Explanation: The document contains negative news regarding a delisting notice and potential share dilution, which outweighs the positive aspect of debt reduction. The overall sentiment is negative.

Positives

• The debt-for-equity swap reduces the company's debt obligations.
• The company has a period of 180 days to regain compliance with Nasdaq listing requirements, with a potential for an additional 180 days.

Negatives

• The company's stock price has fallen below the Nasdaq minimum of $1, triggering a delisting notice.
• The potential conversion of Series C Preferred Stock could significantly dilute existing common shareholders, especially if converted at the floor price.

Risks

• There is a risk that PAVmed will not be able to regain compliance with Nasdaq listing requirements, potentially leading to delisting.
• The potential issuance of a large number of common shares upon conversion of the Series C Preferred Stock could significantly dilute existing shareholders.
• The company's ability to raise capital in the future may be impacted by the delisting notice.

Future Outlook

The company intends to consider all available options to regain compliance with Nasdaq listing standards.

Management Comments

• The company intends to consider all available options to regain compliance with the Nasdaq listing standards.

Industry Context

Delisting notices are not uncommon for companies with struggling stock prices, and companies often explore various options to regain compliance, including reverse stock splits or raising additional capital.

Comparison to Industry Standards

• Many small-cap and micro-cap companies face similar challenges with maintaining Nasdaq listing compliance, especially in volatile market conditions.
• Companies like PAVmed often use debt-for-equity swaps as a way to reduce debt and raise capital, but this can lead to significant dilution for existing shareholders.
• Other companies in the medical device sector have faced similar delisting notices, and their strategies for regaining compliance can be compared to PAVmed's approach.

Stakeholder Impact

• Shareholders face the risk of delisting and potential dilution from the conversion of Series C Preferred Stock.
• Creditors have reduced their debt exposure through the debt-for-equity swap.

Next Steps

• The company will explore options to regain compliance with Nasdaq listing requirements.
• The company will need to maintain a closing bid price of at least $1 for a minimum of ten consecutive business days before July 22, 2025.
• The company may seek an additional 180-day period to regain compliance if needed.

Key Dates

Keywords

Delisting, Nasdaq, Compliance, Preferred Stock, Debt Conversion, Equity Dilution, PAVmed, Series C